Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 18/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14966130 | 0.96 | GPR119 (0.54) | GPR119CYP3A4CYP2C9TP53 | |
| SCHEMBL14970201 | 0.89 | GPR119 (0.49) | GPR119CYP3A4CYP2C9TP53 | |
| SCHEMBL14970194 | 0.89 | GPR119 (0.48) | GPR119TP53 | |
| SCHEMBL14966666 | 0.85 | GPR119 (0.49) | GPR119TP53 | |
| SCHEMBL16163458 | 0.85 | TP53 (0.51) | GPR119CYP3A4CYP2C9TP53 | |
| SCHEMBL14966736 | 0.84 | GPR119 (0.53) | GPR119CYP3A4CYP2C9 | |
| SCHEMBL14970197 | 0.84 | GPR119 (0.55) | GPR119CYP3A4CYP2C9 | |
| SCHEMBL16169605 | 0.83 | TP53 (0.61) | GPR119TP53 | |
| SCHEMBL14978750 | 0.82 | GPR119 (0.39) | GPR119CYP3A4TP53 | |
| SCHEMBL14978690 | 0.82 | GPR119 (0.42) | GPR119TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140309226-A1 | PIPERIDINYL-SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS | ARRAY BIOPHARMA, INC. | 2014-10-16 | — | — | US | disclosed |
| US-20140309226-A1 | PIPERIDINYL-SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS | ARRAY BIOPHARMA, INC. | 2014-10-16 | — | — | US | disclosed |
| US-20140309226-A1 | PIPERIDINYL-SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS | ARRAY BIOPHARMA, INC. | 2014-10-16 | — | — | US | disclosed |
| WO-2013074641-A1 | PIPERIDINYL- SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS | ARRAY BIOPHARMA INC. (US) | 2013-05-23 | — | — | WO | disclosed |
| WO-2013074641-A1 | PIPERIDINYL- SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS | ARRAY BIOPHARMA INC. (US) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309226-A1 | PIPERIDINYL-SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS | GPR119, UTS2R, GPR139 | GPR119 1/4885CYP3A4 3377/4885CYP2C9 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.